Login
$QUCY
$0.96 +$0.05 (6.07%) Close

Company Executives

Management Team

From the 10-K annual report
Officer Age In this role Joined Pay Source
Guido Baechler
Chief Executive Officer and Executive Director
60 Since 2021
5 years
Not stated Not reported
David Lazar Also a director
Chief Executive Officer
Title from the Form 4 dated Aug 5, 2026
35 Not stated Not stated Not reported
William Caragol
Chief Financial Officer
59 Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
5
serving now
Independent
3 of 3
stated in the proxy; 2 not stated
Average tenure
0.0 years
from year joined
CEO also chairs the board
Not stated
no chair stated
Director Age On board Independent Committees Other public boards Pay Source
David Lazar
35 2026
0 years
Not stated None stated None stated Paid as CEO
Robert Liscouski
72 2026
0 years
Independent
Audit Committee Compensation Committee Nomination Committee · Chair
None stated Not stated
David Natan
73 2026
0 years
Independent
Audit Committee · Chair Compensation Committee Nomination Committee
Sunshine Biopharma, Inc. Not stated
Avraham Ben-Tzvi
55 2026
0 years
Independent
Audit Committee Compensation Committee · Chair Nomination Committee
Black Titan Corporation Not stated
Peter O’Rourke
53 2026
0 years
Not stated None stated AXIM Biotechnologies Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Jun 1, 2026
David E. Lazar
Chief Executive Officer and Director
Amount not stated

Private placement of Series A through E Preferred Shares to Mr. Lazar under the Lazar Purchase Agreement

David E. Lazar
Chief Executive Officer and Director
Amount not stated

Voting Agreement among the company, Mr. Lazar and certain stockholders in connection with the Investment

With Voting Shareholders (certain of our stockholders owning approximately 12.4% of our outstanding Ordinary Shares) Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support